Recent regulatory developments include approvals, designations, and submissions for various drugs and medical devices spanning oncology, infectious diseases, and diagnostics. Noteworthy actions include Novartis’ multi-billion dollar deal expansions, new biosimilar approvals, and growth in clinical trials for gene therapies. These regulatory updates reflect ongoing momentum in drug development, accelerated review pathways, and evolving standards for clinical evidence, supporting innovation across multiple therapeutic areas.